What this trial means for you
This study is active, not recruiting — it is not currently taking new participants, but its results may matter for treatments you're considering. It's studying Retatrutide, Tirzepatide for obesity.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: * Have obesity and a history of at least one self-reported unsuccessful dietary effort to reduce body weight. Exclusion Criteria: * Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening. * Have a prior or planned surgical treatment for obesity. * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity. * Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening. * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2). * Have had within the past 90 days before screening: * acute myocardial infarction * cerebrovascular accident (stroke) * coronary revascularization * hospitalization for unstable angina, or * hospitalization due to congestive heart failure. * Have New York Heart Association Functional Classification Class IV congestive heart failure. * Have a history of chronic or acute pancreatitis.
Study sites by state
Arizona
- Medical Advancement Centers of Arizona — Tempe
California
- Mary & Dick Allen Diabetes Center — Newport Beach
- Artemis Institute for Clinical Research — San Diego
- Encompass Clinical Research — Spring Valley
- Diablo Clinical Research, Inc. — Walnut Creek
Colorado
- Lynn Institute of Denver — Aurora
Connecticut
- Bridgeport Hospital — Bridgeport
- Yale University School of Medicine — New Haven
Florida
- Encore Medical Research — Hollywood
- Suncoast Research Group — Miami
- Onhealth Research Center — Miami
- Precision Clinical Research — Sunrise
- Einstein Clinical Research — Vero Beach
Georgia
- ClinCept Clinical Research - MH — Columbus
- Northeast Georgia Medical Center — Gainesville
- Pivotal Research Solutions — Stonecrest
Hawaii
- East-West Medical Research Institute — Honolulu
Illinois
- Northwestern University — Chicago
Iowa
- Integrated Clinical Trial Services, Inc. — West Des Moines
Louisiana
- Pennington Biomedical Research Center — Baton Rouge
Michigan
- Great Lakes Research Group, Inc. — Bay City
- Great Lakes Research Institute — Southfield
Missouri
- StudyMetrix Research — City of Saint Peters
Nevada
- Las Vegas Endocrinology — Henderson
New York
- Albany Medical College, Division of Community Endocrinology — Albany
- New York Gastroenterology Associates — New York
- Westchester Medical Center — Valhalla
North Carolina
- PharmQuest Life Sciences, LLC — Greensboro
- Monroe Biomedical Research — Monroe
- Accellacare - Wilmington — Wilmington
North Dakota
- Lillestol Research — Fargo
Ohio
- PriMED Clinical Research — Dayton
South Carolina
- Tribe Clinical Research, LLC — Greenville
Tennessee
- WR-Clinsearch, LLC — Chattanooga
Texas
- Headlands Horizons LLC — Brownsville
- Next Level Urgent Care — Houston
- Houston Research Institute — Houston
- Consano Clinical Research, LLC — Shavano Park
Utah
- Chrysalis Clinical Research — St. George
Virginia
- Charlottesville Medical Research — Charlottesville
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)